Celcuity(CELC) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update - Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2025 - Expect to reach enrollment target for VIKTORIA-1 PIK3CA WT cohort in Q4 2024 and report topline data for this cohort in late Q4 2024 or Q1 2025 - Raised $129 million ...